Product Description: Filgotinib maleate (GLPG0634 maleate) is a selective, orally available JAK1 inhibitor with anti-inflammatory and antiviral activities. Filgotinib maleate can effectively inhibit the activities of JAK1, JAK2, JAK3 and TYK2 with IC50 values of 10 nM, 28 nM, 810 nM and 116 nM, respectively. Filgotinib maleate also inhibits HIV-1 driven gene transcription and reduces proliferation of HIV-1 infected cells. Filgotinib maleate can be used in the study of rheumatoid arthritis and inflammatory bowel disease[1][2][3].
Applications: COVID-19-immunoregulation
Formula: C25H27N5O7S
References: [1]Van Rompaey L, et, al. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol. 2013 Oct 1;191(7):3568-77./[2]Labetoulle R, et al. Filgotinib for the treatment of Crohn's disease. Expert Opin Investig Drugs. 2018 Mar;27(3):295-300./[3]Yeh, et al. "Filgotinib suppresses HIV-1–driven gene transcription by inhibiting HIV-1 splicing and T cell activation." The Journal of Clinical Investigation 130.9 (2020): 4969-4984.
CAS Number: 1802998-75-9
Molecular Weight: 541.58
Compound Purity: 99.88
Research Area: Inflammation/Immunology
Solubility: DMSO : 35 mg/mL (ultrasonic;warming;heat to 60°C)
Target: HIV;JAK
English
Deutsch
